Kevin began his career in the biotechnology industry at Cambridge Antibody Technology (now part of Medimmune, an AstraZeneca company) when CAT was still in its start-up phase. He went on to found and manage Isogenica Ltd and has since held CEO positions with PhosImmune Inc., Activiomics Ltd and F-star GmbH. Kevin studied for his PhD in the laboratory of Sir Gregory Winter at the MRC Laboratory of Molecular Biology, Cambridge and for his MBA at Aston Business School following receipt of a Sainsbury Management Fellowship from the Royal Academy of Engineering, London.

Dr. Cristina Oliva is a board-certified medical oncologist with over 20 years of international experience in oncology drug development. Her career encompasses senior leadership roles within global pharmaceutical companies, biotechnology firms, and Clinical Research Organizations, where she has successfully advanced numerous oncology and onco-haematology compounds from early clinical stages through to regulatory approval and global market authorization. Cristina has held prominent positions including Vice President and Head of the Oncology Center of Excellence at IQVIA, Chief Medical Officer at Nordic Nanovector, and senior clinical development roles at Shionogi, Takeda Pharmaceuticals, GlaxoSmithKline, and Eli Lilly. Most recently, she served as Chief Medical Officer at BerGenBio, where she was responsible for leading all clinical development activities. She obtained her medical degree and oncology board certification from the University of Genoa in Italy, followed by a Doctorate in Public Health from Kingston University in London.

Nick brings over 30 years of experience in fundraising, public markets and private equity, gained through financial and commercial roles in international pharmaceuticals and technology businesses. Nick was formerly CFO at Midatech Pharma PLC (now Biodexa Pharmaceuticals PLC), a listed pharmaceutical business with operations in the UK and Spain. He successfully steered Midatech through its IPO on AIM, a dual listing on NASDAQ and subsequent fundraises. Nick is a Chartered Accountant and holds a BSc in Pharmacology from Bath University and an MBA.

Elizabeth has more than 15 years’ experience in the pharmaceutical industry. Most recently, Elizabeth was a Senior Director at AstraZeneca leading a team supporting preclinical research in Oncology. Prior to that Elizabeth worked at Evotec in the Inflammation and immunology group and Novartis in the Respiratory group. Throughout her career Elizabeth has been the biology lead on a number of projects from across the drug discovery process ranging from target validation to those in clinical trials. Elizabeth has a PhD from the National Heart and Lung Institute, Imperial College and a Masters in Biochemistry from Bath University.

Leanne has over 20 years’ experience developing therapeutics from bench to clinic. She has worked as a scientist to develop vaccines at the Defence Science and Technology Laboratory (Dstl), GlaxoSmithKline on the development of small molecules and monoclonal antibodies and then the Cell and Gene Therapy Catapult with focus on the translation of cell and gene therapies. Leanne then moved into project management at University College London (UCL), working with academics and clinicians at UCL to secure translational research grants for the development of biologics, cell therapy and medical device modalities and then managing these grants with particular focus on funder liaison and sub-contractor management. She gained her EngD in Biochemical Engineering from University College London and is an APM PMQ qualified project manager.

Andrew has over 25 years of experience in the life sciences industry, holding management and executive positions in both the CRO and biotechnology sector, supporting pharmaceutical development. Andrew started his career within the bioanalytical space before focusing on project management, leading multinational teams responsible for all aspects of clinical trial management in Phase I to Phase III trials. Prior to joining Epsilogen, Andrew worked as an Executive Director of Clinical Development at Syneos Health where he was responsible for the development, oversight, execution and management of several clinical programs for targeted cancer therapies. Andrew holds a BSc in Environment Chemistry from Leeds University.